CN114424825B - Quintuple fat-reducing composition and preparation method and application thereof - Google Patents

Quintuple fat-reducing composition and preparation method and application thereof Download PDF

Info

Publication number
CN114424825B
CN114424825B CN202210342887.7A CN202210342887A CN114424825B CN 114424825 B CN114424825 B CN 114424825B CN 202210342887 A CN202210342887 A CN 202210342887A CN 114424825 B CN114424825 B CN 114424825B
Authority
CN
China
Prior art keywords
parts
component
fat
powder
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210342887.7A
Other languages
Chinese (zh)
Other versions
CN114424825A (en
Inventor
郑雅丹
杨鹏
冯魏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hengmei Health Technology Co ltd
Zhejiang Jimei Food Technology Co ltd
Zhongke Yikang Beijing Biotechnology Co ltd
Original Assignee
Hangzhou Hengmei Food Technology Co ltd
Zhejiang Jimei Food Technology Co ltd
Zhongke Yikang Beijing Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Hengmei Food Technology Co ltd, Zhejiang Jimei Food Technology Co ltd, Zhongke Yikang Beijing Biotechnology Co ltd filed Critical Hangzhou Hengmei Food Technology Co ltd
Priority to CN202210342887.7A priority Critical patent/CN114424825B/en
Publication of CN114424825A publication Critical patent/CN114424825A/en
Application granted granted Critical
Publication of CN114424825B publication Critical patent/CN114424825B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
    • A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
    • Y02P60/87—Re-use of by-products of food processing for fodder production

Abstract

The invention provides a quintuple fat-reducing composition, and relates to the field of food health products. The composition comprises a component A and a component B, wherein the component A comprises a white kidney bean extract, agaricus bisporus concentrated powder, medium-chain triglyceride microcapsule powder and a potato extract; the component B comprises a plurality of medicinal and edible traditional Chinese medicine components such as kudzu root, cassia seed, radish seed, hawthorn and the like, the mass ratio of the component A to the component B is controlled in the implementation process, the absorption of the effective components of the composition can be better promoted through the interaction of the component A and the component B, and the better effects of reducing blood fat and resisting fat are achieved.

Description

Quintuple fat-reducing composition and preparation method and application thereof
Technical Field
The invention relates to the field of food health products, in particular to a quinquex fat-reducing composition and a preparation method and application thereof.
Background
With the change of life style of people, the prevalence rate of obesity is increasing day by day, and various metabolic diseases such as hypertension, hyperlipidemia, diabetes and the like caused by the obesity are more serious threats to human health. The factors causing obesity are numerous, and how to effectively block fat and reduce fat, control body weight and reduce the occurrence of related complications becomes a hot topic of attention of people.
Obesity occurs in association with various factors such as genetic factors, social and environmental factors, psychological factors, etc., but it occurs directly due to energy consumed by intake of energy, so that the excess energy is stored in the form of fat, thereby causing obesity. However, as health consciousness is improved, more and more people realize that obesity becomes a risk factor threatening physical and psychological health of people. At present, weight-losing articles on the market comprise weight-losing medicines and weight-losing health-care foods, and the weight-losing medicines have obvious weight-losing effect but have the defects of large side effect and strong medicine dependence, and are easy to rebound after being taken. The weight-losing health-care food has less side effect and dependence, but the weight-losing effect is not obvious.
Chinese patent application 201710141722.2 discloses a pharmaceutical composition containing orlistat for reducing weight, which contains orlistat and oligosaccharide. Wherein the weight ratio of orlistat to oligosaccharide is 1: 0.1-0.9. On one hand, the weight-losing effect of the pharmaceutical composition containing orlistat and oligosaccharide on the nutritional obese rat is equivalent to that of orlistat, and the oil discharge degree of an animal caused by the pharmaceutical composition provided by the invention is obviously lower than that of orlistat. On the other hand, as a result of in vitro dissolution study, the dissolution behavior of orlistat in the composition containing orlistat and oligosaccharide disclosed in the invention is found to be superior to that of the commercially available orlistat capsule. The orlistat-containing pharmaceutical composition provided by the invention is shown to reduce gastrointestinal adverse reactions on the premise of keeping the weight-reducing effect of currently-marketed orlistat products, but can generate certain dependence on chemical drugs after being taken for a long time.
Chinese patent application 201810506889.9 discloses an L-arabinose composition and preparation with blood sugar and fat reducing effects, wherein L-arabinose is used as a main component, and is quantitatively compatible with Chinese medicinal materials with blood sugar and fat reducing effects, such as radix bupleuri, rhizoma atractylodis macrocephalae, radix polygoni multiflori preparata, hawthorn and the like, so that obvious synergistic effect is generated among active ingredients of the raw material medicines. It can effectively inhibit the absorption of fat and sugar in intestinal tract, accelerate the oxidative decomposition of fat tissue in vivo, and reduce the accumulation of fat in vivo, thereby achieving better effects of reducing blood sugar and fat and improving the health condition of organism. However, the effect of the composition on preventing fat and reducing fat by adding L-arabinose is not obvious.
Chinese patent application 201910658709.3 discloses a composition for reducing weight and blood fat and a preparation method thereof. The feed comprises the following raw materials in parts by weight: 10-100 parts of lotus leaf, 1-50 parts of radish seed, 1-50 parts of hawthorn, 1-50 parts of poria cocos, 1-50 parts of coix seed and 1-30 parts of orange peel; also comprises 3-30 parts of konjak powder and 3-15 parts of an anticaking agent; the weight-losing and lipid-lowering composition has good effects on simple obesity and postpartum obesity, but the raw materials used in the composition are all traditional Chinese medicines, are not suitable for being taken by specific groups in the aspects of taste and safety, and have the problem of low bioavailability.
Therefore, aiming at the problems of unobvious effect and low bioavailability of the fat-reducing and fat-reducing composition in the prior art, a product with good fat-reducing and fat-reducing effects and quick response needs to be searched, so that the fat-reducing and fat-reducing effects and the weight control can be realized safely and efficiently.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides the quintuple fat-reducing composition and the preparation method and the application thereof.
In order to realize the purpose, the technical scheme adopted by the invention is as follows:
a quintuple fat-reducing composition comprises a component A and a component B, and comprises the following components in parts by weight:
the component A comprises: 1-5 parts of white kidney bean extract, 5-10 parts of agaricus bisporus concentrated powder, 3-6 parts of medium-chain triglyceride microcapsule powder and 10-15 parts of potato extract;
the component B comprises: 2-5 parts of kudzu root, 1-3 parts of cassia seed, 1-3 parts of radish seed and 5-10 parts of hawthorn.
Preferably, the five-weight fat-reducing composition comprises a component A and a component B, and comprises the following components in parts by weight:
the component A comprises: 2-4 parts of white kidney bean extract, 6-9 parts of agaricus bisporus concentrated powder, 4-6 parts of medium-chain triglyceride microcapsule powder and 12-15 parts of potato extract;
the component B comprises: 3-4 parts of kudzu root, 1.5-2.5 parts of cassia seed, 1.5-2.5 parts of radish seed and 6-9 parts of hawthorn.
Preferably, the five-weight fat-reducing composition comprises a component A and a component B, and comprises the following components in parts by weight:
the component A comprises: 2 parts of white kidney bean extract, 9 parts of agaricus bisporus concentrated powder, 6 parts of medium-chain triglyceride microcapsule powder and 15 parts of potato extract;
the component B comprises: 4 parts of kudzu root, 2 parts of cassia seed, 2 parts of radish seed and 8 parts of hawthorn.
In some preferred embodiments, the mass ratio of the A component to the B component is 1-4: 1; preferably 2-3:1, and more preferably 2: 1.
According to the invention, the white kidney bean extract, the agaricus bisporus concentrated powder, the medium-chain triglyceride microcapsule powder and the potato extract are added into the composition, wherein the white kidney bean extract has a good anti-sugar effect; the agaricus bisporus concentrated powder, the medium-chain triglyceride microcapsule powder and the potato extract can achieve the effects of preventing fat absorption, accelerating fat metabolism and enhancing satiety through interaction;
in the implementation process, the mass ratio of the agaricus bisporus concentrated powder to the medium-chain triglyceride microcapsule powder to the potato extract is 1-3:1: 2-5;
preferably, the mass ratio of the agaricus bisporus concentrated powder to the medium chain triglyceride micro-capsule powder to the potato extract is 1.5-2.5:1: 2.4-4.
Still preferably, the mass ratio of the agaricus bisporus concentrated powder, the medium chain triglyceride microcapsule powder and the potato extract is 1.5:1: 2.5.
According to the invention, various traditional Chinese medicine components which are homologous in medicine and food are added in the composition, and the fat-blocking and lipid-lowering effects of the composition are obviously improved through scientific compatibility, and no toxic or side effect or dependence is generated.
Preferably, the mass ratio of the kudzuvine root to the cassia seed to the radish seed to the hawthorn is 1-3:1:1: 4-8; preferably, the mass ratio of the kudzuvine root to the cassia seed to the radish seed to the hawthorn is 2:1:1: 4.
Kudzu root is a common medicinal and edible plant, the water-soluble solid content of the kudzu root contains about 12% of flavonoid compounds including daidzin, daidzein, puerarin and the like, the kudzu root has a good blood fat reducing effect, the effective components of the kudzu root are mainly isoflavone compounds, and the puerarin is one of the main functional components.
The semen cassiae is sweet, bitter, salty and slightly cold in nature and taste, enters liver, kidney and large intestine channels, has the effects of clearing liver and improving eyesight and relaxing bowel, pharmacological research shows that the semen cassiae has the effects of reducing blood fat, reducing blood pressure and the like, and the effective components of the blood fat reducing are semen cassiae anthraquinone compounds, such as dulcin, aurantiamarin, obtusin glycoside and daidzin.
Radish seed has various pharmacological actions of relieving asthma, relieving cough, eliminating phlegm, resisting oxidation, lowering blood pressure, reducing blood fat, resisting inflammation, enhancing gastrointestinal tract power, improving urinary system and the like.
The hawthorn is rich in glycosides, flavonoids, maslinic acid and other active ingredients, can promote the effect and treat dyspepsia, has the health-care effects of resisting oxidation, reducing blood fat, resisting tumors, resisting bacteria and diminishing inflammation and the like, has the effect of reducing blood fat, and has the effect of preventing and treating hyperlipidemia and fatty liver caused by high-fat diet.
In other preferred embodiments, the five-weight fat-reducing composition further comprises the following protein components in parts by weight: 5-15 parts of soybean protein isolate powder and 10-20 parts of concentrated whey protein powder.
Preferably, the five-weight fat-reducing composition further comprises the following protein components in parts by weight: 8-12 parts of soybean protein isolate powder and 12-18 parts of concentrated whey protein powder.
Still preferably, the five-weight fat-reducing composition further comprises the following protein components in parts by weight: 10 parts of soybean protein isolate powder and 15 parts of concentrated whey protein powder.
The soybean protein isolate powder and the concentrated whey protein powder are added into the composition, wherein the concentrated whey protein powder is a complete protein with high absorption rate, has rich branched chain amino acids, and can regulate and control the synthesis of muscle protein of a human body; the soybean protein isolate is one of a few varieties capable of replacing animal protein in vegetable protein, so that the intake of cholesterol and saturated fat is reduced, and balance of nutrition intake is achieved.
As some preferred embodiments, the five-weight fat-reducing composition further comprises the following prebiotic components in parts by weight: 20-30 parts of resistant dextrin, 5-15 parts of polydextrose, 10-15 parts of inulin and 5-15 parts of isomaltooligosaccharide;
preferably, the five-weight fat-reducing composition further comprises the following prebiotic components in parts by weight: 22-28 parts of resistant dextrin, 8-12 parts of polydextrose, 12-15 parts of inulin and 8-12 parts of isomaltooligosaccharide;
still preferably, the five-weight fat-reducing composition further comprises the following prebiotic components in parts by weight: 24-26 parts of resistant dextrin, 10-12 parts of polydextrose, 13-15 parts of inulin and 10-12 parts of isomaltooligosaccharide;
further preferably, the five-weight fat-reducing composition further comprises the following prebiotic components in parts by weight: 25 parts of resistant dextrin, 10 parts of polydextrose, 15 parts of inulin and 10 parts of isomaltooligosaccharide.
In the implementation process of the invention, three prebiotic components including polydextrose, inulin and isomaltooligosaccharide are added into the composition, and the mass ratio of the polydextrose, the inulin and the isomaltooligosaccharide is controlled to be 1:1-3:1, so that the intestinal environment can be effectively improved, the growth of beneficial bacteria can be promoted, and the propagation of harmful bacteria can be inhibited, thereby achieving the effect of reducing blood fat; especially, when the mass ratio of the polydextrose to the inulin to the isomaltooligosaccharide is 1:1.5:1, the effects of reducing blood sugar and preventing fat can be better exerted.
In order to better exert the effects of lipid resistance and lipid lowering, the composition also comprises a synergistic component, wherein the synergistic component is citrus polyphenol and astaxanthin, and the mass ratio of the citrus polyphenol to the astaxanthin is 1:1-3, preferably 1: 2.5; the content of the synergistic component is 1.5-3% of the content of other components of the composition.
As a preferred embodiment, a five-weight fat-reducing composition comprises, in parts by weight:
the component A comprises: 2 parts of white kidney bean extract, 9 parts of agaricus bisporus concentrated powder, 6 parts of medium-chain triglyceride microcapsule powder and 15 parts of potato extract;
and B component: 4 parts of kudzu root, 2 parts of cassia seed, 2 parts of radish seed and 8 parts of hawthorn;
protein component: 10 parts of soybean protein isolate powder and 15 parts of concentrated whey protein powder;
the prebiotics component: 25 parts of resistant dextrin, 10 parts of polydextrose, 15 parts of inulin and 10 parts of isomaltooligosaccharide;
synergistic components: 0.76 part of citrus polyphenol and 1.9 parts of astaxanthin.
The invention also provides a preparation method of the quintuple fat-reducing composition, which comprises the following steps:
(1) drying radix Puerariae, semen Cassiae, Raphani semen and fructus crataegi respectively, pulverizing into powder, and mixing the obtained powders to obtain mixture A;
(2) adding water into the mixture A according to the mass ratio of 1:10-15, soaking for 2-3h, performing ultrasonic extraction at 80-90 ℃ for 1-2h, filtering, collecting filtrate, concentrating the filtrate into thick paste, and drying to obtain a mixture B;
(3) adding a navy bean extract, agaricus bisporus concentrated powder, medium-chain triglyceride microcapsule powder, a potato extract, isolated soy protein powder, concentrated whey protein powder, resistant dextrin, polydextrose, inulin, isomaltooligosaccharide, citrus polyphenol and astaxanthin into the mixture B, and uniformly mixing to obtain the five-weight fat-reducing composition.
The invention also provides application of the quintuple fat-reducing composition in preparing a preparation with fat resistance and fat reduction.
A preparation with weight loss effect comprises the weight loss composition and food or pharmaceutically acceptable adjuvants.
Compared with the prior art, the invention has the beneficial effects that:
(1) the composition comprises a component A and a component B, wherein the component A comprises a white kidney bean extract, an agaricus bisporus concentrated powder, a medium-chain triglyceride microcapsule powder and a potato extract, and the white kidney bean extract has a good function of reducing digestion and absorption of carbohydrates; the combination of the agaricus bisporus concentrated powder, the medium-chain triglyceride microcapsule powder and the potato extract can achieve the effects of preventing fat absorption, accelerating fat metabolism and enhancing satiety through interaction; the component B comprises a plurality of medicinal and edible traditional Chinese medicine components, the fat-reducing and lipid-lowering effects of the composition are obviously improved through scientific compatibility, no toxic or side effect and dependence are generated, the mass ratio of the component A to the component B is controlled in the implementation process, the absorption of the effective components of the composition can be better promoted through the interaction of the component A and the component B, and the better fat-reducing and lipid-lowering effects are achieved;
(2) in the implementation process, the mass ratio of the traditional Chinese medicine components of the kudzu root, the cassia seed, the radish seed and the hawthorn is controlled to be 1-3:1:1:4-8, so that the synergistic effect among the medicine components can be obviously improved, and the lipid-lowering effect of the composition is obviously improved;
(3) in the implementation process, three prebiotic components including polydextrose, inulin and isomaltooligosaccharide are added, the mass ratio of the polydextrose, the inulin and the isomaltooligosaccharide is controlled to be 1:1-3:1, the intestinal environment can be effectively improved, the growth of beneficial bacteria is promoted, the propagation of harmful bacteria is inhibited, and the effect of reducing blood fat is achieved; especially, when the mass ratio of the polydextrose to the inulin to the isomaltooligosaccharide is 1:1.5:1, the effects of reducing blood sugar and preventing fat can be better exerted.
(4) The composition also comprises a synergistic component which is a mixture of citrus polyphenol and astaxanthin, and the two components can accelerate sugar decomposition and reduce blood sugar concentration and can effectively promote absorption of effective components of the medicine, so that the composition has the advantages of good lipid-lowering effect and high efficiency.
(5) The composition provided by the invention comprises a component A, namely a white kidney bean extract, agaricus bisporus concentrated powder, medium-chain triglyceride microcapsule powder and a potato extract; the component B is a medicinal and edible component; and a protein component, a prebiotic component and a synergistic component, can achieve the effects of reducing blood fat by reducing carbohydrate absorption, preventing fat absorption, accelerating fat metabolism, enhancing satiety, reducing appetite, balancing diet and controlling sugar intake, and has the characteristics of low GI, high dietary fiber and high protein.
Detailed Description
The features mentioned above in the description, or the features mentioned in the embodiments, may be combined arbitrarily. All the features disclosed in this specification may be combined in any suitable manner and each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent or similar purpose. Thus, unless expressly stated otherwise, the features disclosed are merely generic examples of equivalent or similar features.
The invention will be further illustrated with reference to the following specific examples. These examples are intended to illustrate the invention and are not intended to limit the scope of the invention. The following examples are conducted under conditions specified, usually according to conventional conditions or according to conditions recommended by the manufacturer. All percentages and fractions are by weight unless otherwise specified.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are exemplary only.
The raw materials used in the invention are all common commercial products.
Example 1A quintuple fat-reducing composition and a process for preparing the same
Comprises the following components in parts by weight:
the component A comprises: 1 part of white kidney bean extract, 5 parts of agaricus bisporus concentrated powder, 3 parts of medium-chain triglyceride microcapsule powder and 10 parts of potato extract;
and B component: 2 parts of kudzu root, 1 part of cassia seed, 1 part of radish seed and 5 parts of hawthorn;
protein component: 15 parts of soybean protein isolate powder and 20 parts of concentrated whey protein powder;
the prebiotics component: 20 parts of resistant dextrin, 5 parts of polydextrose, 10 parts of inulin and 5 parts of isomaltooligosaccharide;
the synergistic components are as follows: 3.09 parts of citrus polyphenol.
The preparation method comprises the following steps:
(1) drying radix Puerariae, semen Cassiae, Raphani semen and fructus crataegi respectively, pulverizing into powder, and mixing the obtained powders to obtain mixture A;
(2) adding water into the mixture A according to the mass ratio of 1:10, soaking for 2h, performing ultrasonic extraction for 2h at 90 ℃, filtering, taking filtrate, concentrating the filtrate into thick paste, and drying to obtain a mixture B;
(3) adding navy bean extract, agaricus bisporus concentrated powder, medium-chain triglyceride microcapsule powder, potato extract, soybean protein isolate powder, concentrated whey protein powder, resistant dextrin, polydextrose, inulin, isomaltooligosaccharide and citrus polyphenol into the mixture B, and uniformly mixing to obtain the five-weight fat-reducing composition
Example 2A quintuple fat reducing composition and a method of preparing the same
Comprises the following components in parts by weight:
the component A comprises: 5 parts of white kidney bean extract, 10 parts of agaricus bisporus concentrated powder, 6 parts of medium-chain triglyceride microcapsule powder and 15 parts of potato extract;
and the component B comprises: 5 parts of kudzu root, 3 parts of cassia seed, 3 parts of radish seed and 10 parts of hawthorn;
protein component: 5 parts of soybean protein isolate powder and 10 parts of concentrated whey protein powder;
the prebiotics component: 26 parts of resistant dextrin, 10 parts of polydextrose, 15 parts of inulin and 12 parts of isomaltooligosaccharide;
the synergistic components are as follows: 2.7 parts of astaxanthin.
The preparation method comprises the following steps:
(1) drying radix Puerariae, semen Cassiae, Raphani semen and fructus crataegi respectively, pulverizing into powder, and mixing the obtained powders to obtain mixture A;
(2) adding water into the mixture A according to the mass ratio of 1:10, soaking for 2h, performing ultrasonic extraction at 90 ℃ for 2h, filtering, taking filtrate, concentrating the filtrate into thick paste, and drying to obtain a mixture B;
(3) adding a navy bean extract, agaricus bisporus concentrated powder, medium-chain triglyceride microcapsule powder, a potato extract, isolated soy protein powder, concentrated whey protein powder, resistant dextrin, polydextrose, inulin, isomaltooligosaccharide and astaxanthin into the mixture B, and uniformly mixing to obtain the five-weight fat-reducing composition.
Example 3A quintuple fat reducing composition and a method of preparing the same
Comprises the following components in parts by weight:
the component A comprises: 2 parts of white kidney bean extract, 9 parts of agaricus bisporus concentrated powder, 6 parts of medium-chain triglyceride microcapsule powder and 15 parts of potato extract;
and B component: 4 parts of kudzu root, 2 parts of cassia seed, 2 parts of radish seed and 8 parts of hawthorn;
protein component: 10 parts of soybean protein isolate powder and 15 parts of concentrated whey protein powder;
probiotic components: 25 parts of resistant dextrin, 10 parts of polydextrose, 15 parts of inulin and 10 parts of isomaltooligosaccharide;
synergistic components: 0.76 part of citrus polyphenol and 1.9 parts of astaxanthin.
The preparation method comprises the following steps:
(1) drying radix Puerariae, semen Cassiae, Raphani semen and fructus crataegi respectively, pulverizing into powder, and mixing the obtained powders to obtain mixture A;
(2) adding water into the mixture A according to the mass ratio of 1:10, soaking for 2h, performing ultrasonic extraction at 90 ℃ for 2h, filtering, taking filtrate, concentrating the filtrate into thick paste, and drying to obtain a mixture B;
(3) adding navy bean extract, agaricus bisporus concentrated powder, medium-chain triglyceride microcapsule powder, potato extract, soy protein isolate powder, concentrated whey protein powder, resistant dextrin, polydextrose, inulin, isomaltooligosaccharide, citrus polyphenol and astaxanthin into the mixture B, and uniformly mixing to obtain the five-weight fat-reducing composition
Example 4A quintuple fat reducing composition and a method of preparing the same
Comprises the following components in parts by weight:
the component A comprises: 4 parts of white kidney bean extract, 6 parts of agaricus bisporus concentrated powder, 4 parts of medium-chain triglyceride microcapsule powder and 12 parts of potato extract;
and B component: 3 parts of kudzuvine root, 2.5 parts of cassia seed, 1.5 parts of radish seed and 6 parts of hawthorn;
protein component: 8 parts of soybean protein isolate powder and 18 parts of concentrated whey protein powder;
the prebiotics component: 22 parts of resistant dextrin, 8 parts of polydextrose, 15 parts of inulin and 8 parts of isomaltooligosaccharide;
synergistic components: 1.18 parts of citrus polyphenol and 0.59 part of astaxanthin.
The preparation method comprises the following steps:
(1) drying radix puerariae, semen cassiae, semen raphani and hawthorn respectively, crushing into powder, and mixing the obtained powder to obtain a mixture A;
(2) adding water into the mixture A according to the mass ratio of 1:10, soaking for 2h, performing ultrasonic extraction for 2h at 90 ℃, filtering, taking filtrate, concentrating the filtrate into thick paste, and drying to obtain a mixture B;
(3) adding navy bean extract, agaricus bisporus concentrated powder, medium-chain triglyceride microcapsule powder, potato extract, soybean protein isolate powder, concentrated whey protein powder, resistant dextrin, polydextrose, inulin, isomaltooligosaccharide, citrus polyphenol and astaxanthin into the mixture B, and uniformly mixing to obtain the five-weight fat-reducing composition
Comparative example 1
The difference from example 3 is that: the mass ratio of the component A to the component B is 0.5:1, namely the component A: 2 parts of white kidney bean extract, 4.2 parts of agaricus bisporus concentrated powder, 2.8 parts of medium-chain triglyceride microcapsule powder and 7 parts of potato extract; and B component: 8 parts of kudzu root, 4 parts of cassia seed, 4 parts of radish seed and 16 parts of hawthorn; other operations and steps are the same as in example 3.
Comparative example 2
The difference from example 3 is that: the mass ratio of the component A to the component B is 5:1, namely the component A: 2 parts of white kidney bean extract, 10 parts of agaricus bisporus concentrated powder, 8 parts of medium-chain triglyceride microcapsule powder and 20 parts of potato extract; and B component: 2 parts of kudzu root, 1 part of cassia seed, 1 part of radish seed and 4 parts of hawthorn; other operations and steps are the same as in example 3.
Comparative example 3
The difference from example 3 is that: the radish seed and the cassia seed are replaced by raspberry and platycodon root, namely 4 parts of kudzuvine root, 2 parts of raspberry, 2 parts of platycodon root and 8 parts of hawthorn, and other operations and steps are the same as those in the embodiment 3.
Comparative example 4
The difference from example 3 is that: the mass ratio of citrus polyphenol to astaxanthin was 1:6, i.e., 0.38 parts citrus polyphenol and 2.28 parts astaxanthin, and the other operations and steps were the same as in example 3.
Comparative example 5
The difference from example 3 is that: the mass ratio of the citrus polyphenol to the astaxanthin is 1: 0.4 parts of citrus polyphenol and 0.76 parts of astaxanthin, and the other operations and steps are the same as those of example 3.
Comparative example 6
The difference from example 3 is that: other operations and steps without adding navy bean extract, agaricus bisporus concentrated powder, medium-chain triglyceride micro-capsule powder and potato extract, namely 4 parts of kudzuvine root, 2 parts of cassia seed, 2 parts of radish seed, 8 parts of hawthorn, 10 parts of isolated soy protein powder, 15 parts of concentrated whey protein powder, 32 parts of resistant dextrin, 10 parts of polydextrose, 15 parts of inulin, 10 parts of isomalto-oligosaccharide, 0.76 part of citrus polyphenol and 1.9 parts of astaxanthin are the same as in example 3.
Effect experiment:
test example 1 Effect of the composition of the present invention on blood lipid of mouse
Experimental animals: c57 BL/6J mice, male, weighing 16-20g, purchased from the institute of laboratory animals, national academy of medical sciences;
experimental drugs: compositions prepared in examples 1-4 and comparative examples 1-6;
grouping experiments: dividing mice into 4 groups at random, adding 10 normal control groups (10), model control groups (10), experimental groups 1-4 and comparison groups 1-6, adding basal feed to the normal control groups, adding high fat feed to the model control groups, experimental groups 1-4 and comparison groups 1-6, feeding for 3 weeks, selecting 5 normal control groups and model control groups at random, weighing, collecting blood by canthus method, and centrifuging blood (4000 r.min)-120 min), taking supernatant, namely serum, and determining the TC level of the serum, wherein when the TC level is obviously increased compared with a normal control group, the molding success is indicated;
the administration method comprises the following steps: after 3 weeks of modeling, basal diet was continuously administered to the normal control group, high-fat diet was continuously administered to the model control group, the pharmaceutical compositions (180 mg/Kg. d) prepared in examples 1 to 4 and comparative examples 1 to 6 were gavaged while high-fat diet was continuously administered to the experimental group 1 to 4 and comparative groups 1 to 6, the same amount of physiological saline was gavaged to the normal control group and the model control group, 1 time per day and 4 weeks were continuously administered, after the last dose of the drug, blood was collected by a heart blood sampling method for each group of mice, and after the mice were left to stand at room temperature for 1.5 hours, the blood was centrifuged (4000 r. min)-120 min) serum was separated and then the levels of TG, TC, HDL-C and LDL-C in the mouse serum were measured using a fully automated biochemical analyzer, see in particular Table 1 below, with no mice dead during the feeding.
TABLE 1 Effect of quintuple fat-reducing compositions on mouse blood lipid levels (average, two decimal places retained)
TG（mmol/L） TC（mmol/L） HDL-C（mmol/L） LDL-C（mmol/L）
Normal control group 0.69 2.10 1.68 0.24
Model control group 0.95 3.62 2.50 0.48
Experimental group 1 0.82 3.10 2.30 0.37
Experimental group 2 0.80 3.12 2.31 0.38
Experimental group 3 0.73 3.00 2.23 0.30
Experimental group 4 0.75 3.05 2.26 0.34
Comparative group 1 0.84 3.13 2.32 0.39
Comparative group 2 0.82 3.14 2.30 0.40
Comparative group 3 0.83 3.13 2.34 0.38
Comparative group 4 0.79 3.09 2.29 0.36
Comparative group 5 0.76 3.10 2.28 0.37
Comparative example 6 0.90 3.20 2.35 0.44
According to the test results in the table 1 above, the levels of TG, TC, HDL-C and LDL-C in the serum of the model control group are obviously increased (TG is increased by 27.3%, TC is increased by 42%, HDL-C is increased by 32.8%, and LDL-C is increased by 50%) compared with the normal control group, which indicates that the mouse modeling is successful.
In order to better prove the lipid-lowering effect of the composition provided by the invention, the contents of TG, TC, HDL-C and LDL-C in mice of an experimental group and a comparative group are calculated relative to the contents of a model group in the following way: the reduction rate (%) = [ (model group value-experimental group or comparative example value)/model group value ] × 100%, and the calculation results are shown in table 2 below.
TABLE 2 reduction rates of TG, TC, HDL-C and LDL-C contents in experimental and control mice relative to model groups
The reduction rate% The reduction rate% The reduction rate% The reduction rate%
TG（mmol/L） TC（mmol/L） HDL-C（mmol/L） LDL-C（mmol/L）
Experimental group 1 13.7 14.4 8.0 22.9
Experimental group 2 15.8 13.8 7.6 20.8
Experimental group 3 23.2 17.1 10.8 37.5
Experimental group 4 21.1 15.7 9.6 29.2
Comparative group 1 11.6 13.5 7.2 18.8
Comparative group 2 13.7 13.3 8.0 16.7
Comparative group 3 12.6 13.5 6.4 20.8
Comparative group 4 16.8 14.6 8.4 25.0
Comparative group 5 20.0 14.4 8.8 22.9
Comparative example 6 5.2 11.6 5.4 8.3
According to the results of the tests and calculations in table 2 above, it can be seen that the compositions prepared in examples 3-4 of the present invention have four better effects of reducing blood lipid, especially the composition prepared in example 3 has the best effect of reducing blood lipid;
the synergistic component is added in the middle of the examples 1-2, so that the synergistic composition has a certain effect of inhibiting lipid lowering, but the effect is equivalent to that of the comparative examples 3-4, and the effect of the lipid lowering effect of the composition is influenced when the type or the mass ratio of the synergistic component is not within the protection range of the application;
in comparative examples 1-2, the change of the mass ratio of the component A to the component B can obviously influence the lipid-lowering effect of the composition, and especially, the comparative example 2 can obviously influence the lipid-lowering effect of the composition by obviously reducing the content of the traditional Chinese medicine components;
compared with the blood fat reducing effect of the embodiment 3, the blood fat reducing effect of the embodiment 3 is obviously reduced when the types of the traditional Chinese medicine components are changed, which shows that the types of the traditional Chinese medicine components have great influence on the blood fat reduction;
comparative examples 4 to 5 change the mass ratio of the enhancer to obtain compositions which have significantly reduced lipid-lowering effects compared to example 3, but have better lipid-lowering effects compared to examples 1 to 2, which shows that the lipid-lowering effect of the composition added with two synergistic components is significantly better than that of one synergistic component, and better effect can be achieved only by the synergistic components in a specific ratio.
The composition of comparative example 6, to which the white kidney bean extract, the agaricus bisporus concentrated powder, the medium chain triglyceride micro-capsule powder and the potato extract were not added, had the worst lipid-lowering effect; the composition prepared by the optimal technical scheme disclosed by the invention has better effects of reducing fat and resisting fat.
Test example 3 Effect of the composition of the present invention on body weight of mouse
In order to observe the effect of the composition prepared by the present invention on the body weight of mice more intuitively, the average body weight of the mice after administration of the composition to the mice was counted once every 7 days, and see table 3 below.
Growth = body weight of mice after 49 days-body weight of mice at 21 days
TABLE 3 Effect of quintuple weight loss compositions on average body weight of mice (g)
21 days 28 days 35 days 42 days For 49 days Growth value
Normal control group 18.8 19.2 19.9 20.8 22.5 3.7
Model control group 21.5 22.6 23.8 24.8 25.9 4.4
Experimental group 1 21.6 22.4 23.1 23.9 24.4 2.8
Experimental group 2 21.5 22.2 22.9 23.5 24.0 2.5
Experimental group 3 21.6 22.0 22.2 22.3 22.5 0.9
Experimental group 4 21.8 22.2 22.5 22.8 23.0 1.2
Comparative group 6 21.7 22.5 23.2 23.8 24.8 3.1
According to the detection data in the table 2, the normal control group is fed with the basal feed, the weight of the mouse increases slowly, while the model control group is fed with the high-fat feed, the weight of the mouse increases obviously, and the success of the mouse in membrane formation is further illustrated; in experimental groups 1 to 4, after feeding the mice with the high-fat diet for 3 weeks, the mice were administered with the compositions prepared in examples 1 to 4, and the data in the table show that the weight gain of the mice in the model group was decreased at 28 days and significantly decreased at 49 days, indicating that the administration of the composition can inhibit the weight gain; particularly, in the experimental group 3, after the mice are fed with the high-fat diet for 3 weeks, the weight gain of the mice in the model group is obviously reduced at 28 days, and the weight gain of the mice in the model group is minimum at 49 days, which indicates that the weight gain can be obviously inhibited and the weight reducing effect is better when the composition prepared in the example 3 is taken. The body weight gain of the composition prepared in comparative example 6 was lower than that of the model group, but still higher than that of examples 1 to 3, and the lipid-lowering effect was not significant, which is in agreement with the results in table 2.
Test example 3 Effect of the composition of the present invention on the food intake of mice
In order to more visually observe the effect of the composition prepared by the present invention on the food intake of mice, statistics were made on the average food intake of mice after administration of the mice, see table 4 below.
TABLE 4 Effect of quintuple fat-reducing compositions on average food intake (g) in mice
Day 0 1 day 2 days 3 days 4 days 5 days 6 days 7 days 8 days 9 days 10 days Mean value of
Model control group 8.2 8.2 8.0 8.1 8.2 8.3 8.2 8.1 8.2 8.3 8.4 8.20
Experimental group 1 8.2 8.0 7.9 7.7 7.5 7.6 7.2 7.3 7.5 7.6 7.5 7.64
Experimental group 2 8.1 7.8 7.6 7.7 7.5 7.6 7.3 7.2 7.3 7.0 7.1 7.47
Experimental group 3 8.2 7.7 7.5 7.5 7.3 7.2 7.0 7.2 7.0 6.8 6.5 7.26
Experimental group 4 8.0 7.8 7.5 7.6 7.5 7.3 7.2 7.1 7.0 6.9 6.6 7.31
Comparative group 1 8.2 7.9 7.7 7.6 7.6 7.5 7.4 7.3 7.3 7.2 7.3 7.55
Comparative group 2 8.3 8.0 7.9 7.8 7.8 7.7 7.6 7.5 7.3 7.3 7.1 7.66
Comparative example 3 8.2 8.1 7.9 7.8 7.6 7.6 7.5 7.5 7.5 7.5 7.4 7.69
Comparative group 6 8.2 8.1 7.8 7.8 7.7 7.6 7.6 7.7 7.5 7.5 7.4 7.72
According to the detection data in the above table 4, it can be seen that the food intake of the mice is affected by taking the compositions prepared in the examples and the comparative examples, and the food intake of the mice is reduced with the time, which indicates that the compositions prepared in the invention can suppress the appetite of the mice to a certain extent, so as to reduce the food intake, thereby achieving the effects of fat reduction and fat reduction, and as can be seen from the above table 4, the compositions prepared in the examples 3-4 of the invention can better suppress the appetite of the mice, and have better effects of fat reduction and fat reduction.
According to the detection results, the five-element fat-reducing composition and the preparation method thereof provided by the invention have the advantages that the white kidney bean extract, the agaricus bisporus concentrated powder, the medium-chain triglyceride micro-capsule powder, the potato extract, the radix puerariae, the semen cassiae, the semen raphani, the hawthorn, the isolated soy protein powder, the concentrated whey protein powder, the resistant dextrin, the polydextrose, the inulin, the isomaltooligosaccharide, the citrus polyphenol and the astaxanthin are mixed according to a specific proportion, so that the absorption of effective components of the medicine can be effectively promoted, the appetite of mice can be inhibited to a certain degree, the purposes of reducing the contents of TG, TC, HDL-C and LDL-C in serum can be achieved, and the effects of fat resistance and fat reduction can be further achieved.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims (4)

1. A quintuple fat reducing composition, characterized by: the five-weight fat-reducing composition consists of a component A, a component B, a protein component, a prebiotics component and a synergistic component, and comprises the following components in parts by weight:
the component A comprises: 2 parts of white kidney bean extract, 9 parts of agaricus bisporus concentrated powder, 6 parts of medium-chain triglyceride microcapsule powder and 15 parts of potato extract;
and B component: 4 parts of kudzu root, 2 parts of cassia seed, 2 parts of radish seed and 8 parts of hawthorn;
protein component: 10 parts of soybean protein isolate powder and 15 parts of concentrated whey protein powder;
probiotic components: 25 parts of resistant dextrin, 10 parts of polydextrose, 15 parts of inulin and 10 parts of isomaltooligosaccharide;
synergistic components: 0.76 part of citrus polyphenol and 1.9 parts of astaxanthin.
2. A quintuple fat reducing composition, characterized by: the five-weight fat-reducing composition consists of a component A, a component B, a protein component, a prebiotics component and a synergistic component, and comprises the following components in parts by weight:
the component A comprises: 4 parts of white kidney bean extract, 6 parts of agaricus bisporus concentrated powder, 4 parts of medium-chain triglyceride microcapsule powder and 12 parts of potato extract;
and the component B comprises: 3 parts of kudzuvine root, 2.5 parts of cassia seed, 1.5 parts of radish seed and 6 parts of hawthorn;
protein component: 8 parts of soybean protein isolate powder and 18 parts of concentrated whey protein powder;
the prebiotics component: 22 parts of resistant dextrin, 8 parts of polydextrose, 15 parts of inulin and 8 parts of isomaltooligosaccharide;
synergistic components: 1.18 parts of citrus polyphenol and 0.59 part of astaxanthin.
3. A method of preparing a quintuple fat reducing composition of claim 1 or 2, wherein: the method comprises the following steps:
(1) drying radix Puerariae, semen Cassiae, Raphani semen and fructus crataegi respectively, pulverizing into powder, and mixing the obtained powders to obtain mixture A;
(2) adding water into the mixture A according to the mass ratio of 1:10-15, soaking for 2-3h, performing ultrasonic extraction at 80-90 ℃ for 1-2h, filtering, collecting filtrate, concentrating the filtrate into thick paste, and drying to obtain a mixture B;
(3) adding a navy bean extract, agaricus bisporus concentrated powder, medium-chain triglyceride microcapsule powder, a potato extract, isolated soy protein powder, concentrated whey protein powder, resistant dextrin, polydextrose, inulin, isomaltooligosaccharide, citrus polyphenol and astaxanthin into the mixture B, and uniformly mixing to obtain the five-weight fat-reducing composition.
4. Use of the quintuple fat-reducing composition according to claim 1 or 2 and the quintuple fat-reducing composition prepared by the preparation method according to claim 3 for preparing a fat-reducing preparation.
CN202210342887.7A 2022-04-02 2022-04-02 Quintuple fat-reducing composition and preparation method and application thereof Active CN114424825B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210342887.7A CN114424825B (en) 2022-04-02 2022-04-02 Quintuple fat-reducing composition and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210342887.7A CN114424825B (en) 2022-04-02 2022-04-02 Quintuple fat-reducing composition and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN114424825A CN114424825A (en) 2022-05-03
CN114424825B true CN114424825B (en) 2022-07-05

Family

ID=81314423

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210342887.7A Active CN114424825B (en) 2022-04-02 2022-04-02 Quintuple fat-reducing composition and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN114424825B (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102150838A (en) * 2010-12-16 2011-08-17 北京康比特体育科技股份有限公司 Weight losing composition, preparation containing same and preparation method thereof
CN109601827A (en) * 2018-11-27 2019-04-12 微普安全科技（徐州）股份有限公司 A kind of oatmeal and preparation method thereof being suitble to three high crowds
CN110447902B (en) * 2019-09-10 2024-02-20 广州宏韵医药科技股份有限公司 Composition with weight-losing effect
CN111084381A (en) * 2019-12-18 2020-05-01 东莞自然衡健康科技有限公司 Ketogenic nutritional meal replacement powder and application
CN112137083A (en) * 2020-09-15 2020-12-29 广东绿宝堂健康科技有限公司 Meal replacement composition and application thereof
CN114098056A (en) * 2021-01-14 2022-03-01 海南田井坊养生产业有限公司 Traditional Chinese medicine health-preserving dietary therapy formula for improving three highs
CN113598253A (en) * 2021-07-14 2021-11-05 云南润攀生物科技有限公司 Ketogenic herbal tea for promoting ketogenic effect and increasing body fat decomposition
CN113826799A (en) * 2021-09-26 2021-12-24 山东森健生物科技发展有限公司 Diet food
CN114208989A (en) * 2021-12-27 2022-03-22 华润圣海健康科技有限公司 Ketogenic meal replacement nutrition powder solid beverage and preparation method thereof

Also Published As

Publication number Publication date
CN114424825A (en) 2022-05-03

Similar Documents

Publication Publication Date Title
CN104026446B (en) A kind of it is suitable for nutritional meal replacement powder that hyperglycemia population takes and preparation method thereof
CN106858620A (en) A kind of anaemia tailored version clinical nutrition formula and preparation method thereof
CN104799146A (en) Functional nutritional good composition for improving sub-health and preparation method thereof
KR102262306B1 (en) Composition for relieving premenstrual syndrome and menstrual pain
CN106036420A (en) Tartary buckwheat health care food applicable to diabetics and preparation method thereof
CN111840363B (en) Natto-assisted hypoglycemic health-care composition and preparation method and application thereof
KR20030080290A (en) Composition containing an extract of specially treated ginseng for preventing brain cells and treating brain stroke
CN109393494A (en) A kind of person in middle and old age's health-care food composition and its application
CN101766274B (en) Antioxidant functional food composition containing bamboo-leaves flavones
CN107373672A (en) A kind of irregular menstruation women tailored version clinical nutrition formula and preparation method thereof
CN100444746C (en) A refined health food of high and cold mountain area crop and processing technology thereof
CN111096416A (en) Diet-depriving composition for weight-losing meal replacement and preparation method thereof
CN102188486B (en) Pharmaceutical composition for preventing and treating fatty liver and preparation method thereof
CN110051815A (en) A kind of auxiliary hyperglycemic food ball and preparation method thereof
CN114424825B (en) Quintuple fat-reducing composition and preparation method and application thereof
CN112704717A (en) Stomach-invigorating medicinal and edible composition for assisting treatment of advanced digestive tract tumor
CN104585574A (en) Propolis soft capsule product and preparation method thereof
CN113598372A (en) Composition for intervening hyperglycemia and preparation method thereof
CN108095075A (en) Miscarriage women tailored version clinical nutrition formula and preparation method thereof
CN108208655A (en) A kind of pure natural functional food with lower hyperlipidemia, hypertension, hyperglycemia and preparation method thereof
CN113080449A (en) Pure natural plant solid meal replacement bag capable of reducing blood sugar, blood fat and blood viscosity
CN105267968A (en) Natural medicine composition with weight reducing effect
CN105638961A (en) Dark green tea composition with ramie leaves and preparation method thereof
CN105494819B (en) Black tartary buckwheat compound tea beverage and preparation method thereof
CN114306544B (en) Hypoglycemic composition and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: 100176 1505, floor 15, building 2, courtyard 11, Tianhua North Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing

Patentee after: ZHONGKE YIKANG (BEIJING) BIOTECHNOLOGY Co.,Ltd.

Patentee after: Zhejiang Hengmei Health Technology Co.,Ltd.

Patentee after: Zhejiang Jimei Food Technology Co.,Ltd.

Address before: 100176 1505, floor 15, building 2, courtyard 11, Tianhua North Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing

Patentee before: ZHONGKE YIKANG (BEIJING) BIOTECHNOLOGY Co.,Ltd.

Patentee before: HANGZHOU HENGMEI FOOD TECHNOLOGY Co.,Ltd.

Patentee before: Zhejiang Jimei Food Technology Co.,Ltd.

CP01 Change in the name or title of a patent holder
TR01 Transfer of patent right

Effective date of registration: 20230711

Address after: 311113 No.8, Weiliu Road, Liangzhu street, Yuhang District, Hangzhou City, Zhejiang Province

Patentee after: Zhejiang Hengmei Health Technology Co.,Ltd.

Patentee after: Zhejiang Jimei Food Technology Co.,Ltd.

Address before: 100176 1505, floor 15, building 2, courtyard 11, Tianhua North Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing

Patentee before: ZHONGKE YIKANG (BEIJING) BIOTECHNOLOGY Co.,Ltd.

Patentee before: Zhejiang Hengmei Health Technology Co.,Ltd.

Patentee before: Zhejiang Jimei Food Technology Co.,Ltd.

TR01 Transfer of patent right